EFA Technologies Goes in Brazilian Market Post Anvisa Approval

EFA Technologies Goes in Brazilian Market Post Anvisa Approval

By, Admin 15 April 2024

EFA Technologies enters Brazilian market after Anvisa approval of its portable RevDx device

Overview 

EFA Technologies, pioneers in portable blood labs, announces the start of its operations in Brazil, following approval last October of its leading portable blood lab device, RevDx, by Anvisa, the Brazilian health regulatory authority. The company also secured US$ 6.5 million in funding, boosting EFA’s mission to further improve healthcare worldwide.

RevDx, EFA’s flagship product, is a sophisticated portable diagnostic device that leverages advanced technology to provide accurate and rapid medical testing locally. Its capabilities include identifying pathogens, analyzing biomarkers and aiding in disease diagnosis. Thereby revolutionizing the field of on-site diagnostics with its efficiency and precision.

RevDx

  • RevDx marks a significant breakthrough in medical diagnostics. It is portable, affordable and user-friendly, leveraging microscopy and AI to deliver instant results. 
  • This not only reduces costs and saves time, but also improves the doctor-patient relationship.
  • With the capability to perform a full CBC count from just a single drop of blood, the device streamlines diagnostics and equips healthcare professionals with actionable insights.

Words from CEO: EFA Technologies

Yoel Ezra, CEO of EFA Technologies, said: ""We’re thrilled to witness the impact of RevDx's on healthcare. Our mission to make Medtech accessible to everybody, starting with a complete blood count test (CBC), is coming to fruition. We’re dedicated to further expanding our reach for the benefit of patients and caregivers worldwide. Entering the vast and promising Brazilian market is a testament to that.""

Guidance by Nobel Laureate

  • Backed by a distinguished medical board that includes Prof. Aaron Ciechanover, a 2004 Nobel Prize Laureate, EFA Technologies is poised to revolutionize healthcare on a global scale. Prof. Ciechanover's endorsement underscores the significance of RevDx's medical innovation.The potential of this 'little' device is enormous,"says Prof. Ciechanover. It opens doors to myriad clinical applications, simplifying complex processes and transforming patient care.

EFA Technologies has obtained CE certification and enters the Brazilian market with Anvisa certification for RevDx. Meanwhile, EFA is actively exploring new markets for further expansion.

From CMO: EFA

Amir Lubshevsky, EFA’s chief medical officer, adds: We're thrilled by the initial positive response from the Brazilian market. It's an exciting time for EFA Technologies as we enter this promising market. We're eager to solidify our presence and welcome further international interest in our innovative solutions.

Current Investors and Funds

  • In addition, EFA has secured another US$ 6.5 million in growth capital. The current round was led by existing investors and new partners such as E-Health Ventures, Venturing Tech, ARC impact ventures and the Israeli Innovation Authority. 
  • This capital injection will accelerate product development, expand market reach and foster innovation in healthcare diagnostics.

RevDx Capabilities

  • RevDx is a sophisticated portable diagnostic device that leverages advanced technology to provide accurate and rapid medical testing locally. 
  • Its capabilities include identifying pathogens, analyzing biomarkers and aiding in disease diagnosis. 
  • Thereby revolutionizing the field of on-site diagnostics with its efficiency and precision.

About EFA

EFA (Engineering for All) Technologies, based in Caesarea, Israel,  was established in 2016 by a team with combined experience in medical sciences, optical and bioengineering, and a vision to bring access to proper diagnostic and healthcare to all.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!